Erythritol-based dry powder of glucagon for pulmonary administration
Authors:
- Satomi OnoueSOSatomi Onoue
- 1 February 2005
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 290 (1-2) , 63-71
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout miceProceedings of the National Academy of Sciences, 2003
- Caveolae as potential macromolecule trafficking compartments within alveolar epitheliumAdvanced Drug Delivery Reviews, 2001
- Effects of glucagon, insulin, amylin and CGRP on feedingNeuropeptides, 1999
- Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrateInternational Journal of Pharmaceutics, 1998
- Endoproteolysis of Glucagon-like Peptide (GLP)-1(7–36) amide by Ectopeptidases in RINm5F CellsPeptides, 1997
- Effects of Oral Administration of Erythritol on Patients with DiabetesRegulatory Toxicology and Pharmacology, 1996
- Glucagon receptor mRNA distribution in rat tissuesPeptides, 1995
- Glucagon in the metabolic and nutritional management after total pancreatectomy —A case report—Surgery Today, 1989
- Glucagon deficiency and hyperaminoacidemia after total pancreatectomy.Journal of Clinical Investigation, 1980
- Formation and Structure of Gels and Fibrils from GlucagonEuropean Journal of Biochemistry, 1969